Based on the current evidence, there is no consistent association between vaccines and serious or long-term health outcomes.

Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten ...

HealthDay News — As an investigation continues into a hantavirus outbreak that killed three passengers and sickened five on an ocean liner, the World Health Organization (WHO) says the odds of broader ...

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Relative vaccine efficacy was 26.6 percent, which met the criteria for noninferiority, superiority, higher-level superiority.

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.

It’s also not clear that HHS has the regulatory authority to enforce its threat without going through a formal rulemaking process, lawyers and dietitians say.

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

A larger percentage of patients in PFA group had treatment success at 12 months compared with those receiving antiarrhythmic-drug therapy.

Botulinum toxin may slightly reduce monthly migraine days but has higher discontinuation rates due to adverse events.

The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.